Clarithromycin SR, 500 mg 7 pcs

An antibiotic of the macrolide group with delayed release. Mechanism of action is inhibition of protein synthesis in microbial cell by interaction with ribosomal 50S-subunit of bacteria.

The minimum inhibitory concentration (MIC) of clarithromycin is 2 times lower than the MIC of erythromycin. Clarithromycin metabolite 14-hydroxyclarithromycin, has antimicrobial activity. Clarithromycin has a broad spectrum of antimicrobial activity.

The drug is active against Gram-positive microorganisms: Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, alpha-hemolytic streptococci, Listeria monocytogenes; Gram-negative microorganisms: Haemophilus influenzae, Haemophilus parainfluenzae, Helicobacter pylori, Moraxella (Branhamella) catarrhalis, Neisseria gonorrhoeae, Legionella pneumophila, Bordetella pertussis; intracellular microorganisms: Mycoplasma pneumoniae, Ureaplasma urealyticum, Chlamydia trachomatis, Chlamydia pneumoniae, Mycobacterium avium, Mycobacterium leprae, Mycobacterium kansasii, Mycobacterium chelonae, Mycobacterium fortuitum, Mycobacterium intracellulare; anaerobic microorganisms: Clostridium perfringens, Peptococcus species, Peptostreptococcus species , Propionibacterium acnes, Bacteroides melaninogenicus; other microorganisms: Borrelia burgdorferi, Treponema pallidum.

Indications

Infectious and inflammatory diseases caused by microorganisms sensitive to the drug:

– respiratory tract infections (sinusitis, pharyngitis, bronchitis, pneumonia);

– skin and soft tissue infections (folliculitis, rust);

– Helicobacter pylori-associated diseases of the stomach and duodenum.

Active ingredient

Composition

1 tablet contains:

The active ingredient:

clarithromycin 500 mg.

Associates:

Hypromellose 2208 (100 mPa-s) 200 mg,

Hypromellose (hydroxypropyl methylcellulose) 2910 (50 mPa-s) 150 mg,

Microcrystalline cellulose 137.5 mg,

colloidal silicon dioxide 2.5 mg,

magnesium stearate 10 mg.

Composition of the film coating:

Hypromellose 2910 (6 mPa-s) 15 mg,

Hyprolose 5.82 mg,

talc 5.778 mg,

titanium dioxide 3.261 mg,

iron oxide yellow 0.141 mg

How to take, the dosage

Clarithromycin SR is administered orally to adults and children over 18 years of age in a dose of 500 mg (1 tablet) with meals. If necessary, the dose may be increased to 1 g (2 tablets) per dose or in 2 doses with an interval of 12 hours. Average daily dose is 500 mg. Maximum daily dose is 1 g.

The duration of treatment is usually 7-14 days.

Interaction

In concomitant use with Clarithromycin SR:

-Drugs metabolized with participation of cytochrome P450 isoenzymes (cilostazol, methylprednisolone, quinidine, sildenafil, ergot alkaloids, alprazolam, triazolam, midazolam, disopyramide, lovastatin, rifabutin, phenytoin, cyclosporine, vinblastine, valproate and tacrolimus) may increase their plasma concentrations;

Theophylline, digoxin, carbamazepine, colchicine may increase their plasma concentrations;

Warfarin may increase the effect of warfarin (prothrombin time control is necessary);

-quinidine or disopyramide – possible ventricular tachycardia;

-ergotamine or dihydroergotamine – increase in their effects with the development of vasospasm;

-ritonavir – possible increase in clarithromycin concentrations (for this combination, the dose of Clarithromycin SR-ritofarm should not exceed 500 mg/);

Cisapride, pimozide – possible increased QT interval, arrhythmias, ventricular tachycardia, fibrillation, torsade de pointes;

Participants with oral clarithromycin and zidovudine have lower plasma zidovudine concentrations in HIV-infected patients.because clarithromycin affects absorption of zidovudine (interval between doses of these drugs should be at least 4 hours).

Cross-resistance may develop between clarithromycin, lincomycin and clindamycin.

Special Instructions

Caution is necessary when using Clarithromycin SR in patients with hepatic and renal dysfunction.

In case of co-administration with warfarin or other anticoagulants, prothrombin time should be monitored.

Influence on driving and operating ability

No effect.

Contraindications

– porphyria;

– renal insufficiency (CK less than 30 ml/min);

– simultaneous use of cisapride, pimozide and terfenadine, astemizole, ergotamine and other ergot alkaloids;

Fructose intolerance, impaired glucose-galactose absorption or sucrase-isomaltase deficiency;

– first trimester of pregnancy;

– lactation (breastfeeding) period;

– childhood under 18 years of age;

p> – hypersensitivity to the components of the drug;

– hypersensitivity to antibiotics from the macrolide group.

Side effects

Often: headache, dizziness, anxiety, fear; nausea, vomiting, abdominal pain, diarrhea.

Sometimes: candida stomatitis, glossitis, discoloration of tongue and teeth; arthralgia, myalgia; skin rash, urticaria; paresthesia, perversion of taste, visual disturbances; increased liver transaminase activity, plasma creatinine content.

Rarely: Insomnia, tinnitus, uveitis; disorientation, hallucinations, psychosis, depersonalization, confusion; tachycardia, ventricular arrhythmia; pseudomembranous enterocolitis, hepatitis, cholestatic jaundice, pancreatitis; interstitial nephritis, renal failure; hypoglycemia, leukopenia, thrombocytopenia; Stevens-Johnson syndrome (malignant exudative erythema) and toxic epidermal necrolysis.

In isolated cases: hearing loss, which disappears after discontinuation of the drug.

Overdose

Symptoms: nausea, vomiting, abdominal pain, diarrhea, headache, confusion.

Treatment: gastric lavage, symptomatic therapy.

Similarities